Kymera Therapeutics (KYMR) Long-Term Investments (2020 - 2026)

Kymera Therapeutics (KYMR) has 7 years of Long-Term Investments data on file, last reported at $894.7 million in Q1 2026.

• On a quarterly basis, Long-Term Investments rose 186.46% year-over-year to $894.7 million in Q1 2026; TTM through Mar 2026 was $894.7 million, a 186.46% increase from a year earlier, with the FY2025 full-year figure at $771.2 million, up 112.91% from the prior year.
• Long-Term Investments for Q1 2026 stood at $894.7 million, up from $771.2 million in the prior quarter.
• Over the last five years, Long-Term Investments for KYMR reached as high as $894.7 million in Q1 2026 and fell as low as $61.4 million in Q1 2023.
• Historically, Long-Term Investments has averaged $273.7 million across 5 years, with a median of $192.4 million in 2024.
• Across the five-year window, Long-Term Investments plunged 59.67% in 2023 and surged 489.58% in 2024, its largest moves.
• Year by year, Long-Term Investments stood at $152.3 million in 2022, then tumbled by 59.67% to $61.4 million in 2023, then jumped by 489.58% to $362.2 million in 2024, then jumped by 112.91% to $771.2 million in 2025, then rose by 16.02% to $894.7 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $894.7 million in Q1 2026, $771.2 million in Q4 2025, and $473.1 million in Q3 2025.